Trethera’s first combination therapy targets the alternative pathways of nucleotide biosynthesis. TRE-515, is an oral, small molecule inhibitor of Deoxycytidine Kinase, the key enzyme in the nucleotide salvage pathway. In combination with specific inhibitors of the de novo pathway of nucleotide synthesis, TRE-515 demonstrates robust anti-tumor effects in animal models of leukemia. TRE-515 is advancing through preclinical development and represents a breakthrough toward improving the safety and efficacy of anti-cancer therapies.
Download our factsheet